Skip to main content

Table 2 Mean utility (EQ-5D) values extrapolated from MSQ and HIT-6

From: Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials

Week, mean (SD)PlaceboErenumab 70 mgErenumab 140 mg
MSQHIT-6MSQHIT-6MSQHIT-6
00.615 (0.173)0.671 (0.136)0.633 (0.163)0.677 (0.125)0.617 (0.176)0.675 (0.145)
40.675 (0.161)0.721 (0.135)0.716 (0.142)0.747 (0.125)0.716 (0.154)0.761 (0.147)
80.687 (0.160)0.732 (0.137)0.726 (0.141)0.771 (0.133)0.729 (0.153)0.775 (0.147)
120.687 (0.160)0.734 (0.139)0.730 (0.146)0.776 (0.134)0.737 (0.144)0.787 (0.145)
160.736 (0.120)0.781 (0.119)0.765 (0.111)0.810 (0.122)0.775 (0.094)0.828 (0.114)
200.731 (0.127)0.786 (0.128)0.771 (0.100)0.813 (0.121)0.776 (0.093)0.824 (0.114)
240.729 (0.129)0.781 (0.132)0.763 (0.111)0.812 (0.122)0.776 (0.091)0.824 (0.114)
  1. Abbreviations: EQ-5D 5-dimension EuroQol questionnaire, HIT-6 Headache Impact Test, MSQ Migraine-Specific Quality of Life Questionnaire, SD standard deviation